Jump to content

Drilldown: Medicines

Choose a table:


Medicines > mechanism: None & pregnancy : Limited data or None

Use the filters below to narrow your results.

generic:
None (3) · Amobarbital (1) · Butalbital (1) · Curare (1) · Doxycycline (1) · Esmolol (1) · Ethchlorvynol (1) · Fluconazole (1) · Glutethimide (1) · Lixisenatide (1) · Nadolol (1) · Ondansetron (1) · Paracetamol (1) · Phencyclidine (1) · Piroxicam (1) · Progesterone (micronized) (1) · Sotalol (1) · Tretinoin (all-trans retinoic acid, ATRA) (1) · Warfarin (1)
brand:
None (3) · Amytal (1) · Betapace (1) · Brevibloc (1) · Corgard (1) · Coumadin (discontinued in US but name in common use), Jantoven (1) · Diflucan (1) · Doriden (1) · Feldene (1) · Kisunla (1) · Leqembi (1) · Placidyl (1) · Prometrium (oral), Endometrin (vaginal), Crinone (vaginal gel), Prochieve (1) · Retin-A, Renova, Atralin, Avita, Tretin-X, Refissa, Altreno; Vesanoid (oral, APL) (1) · Sernyl (human, withdrawn 1965); Sernylan (veterinary, withdrawn 1978) (1) · Tylenol, Panadol (1) · Vibramycin, Doryx, Oracea, Adoxa, Monodox, Acticlate (1) · Vraylar (1) · Zofran, Zofran ODT (1)
classes:
Analgesic / antipyretic (1) · Anti-amyloid beta (Aβ) monoclonal antibody (2) · APL)]] (1) · Atypical antipsychotic (1) · Barbiturate (2) · Beta blocker (3) · D2/D3/5HT1A partial agonist (1) · GLP-1 receptor agonist (1) · Neuromuscular blocker (1) · NSAID (1) · Sedative-hypnotic (2) · targets protofibrils (1) · targets pyroglutamated Aβ in plaques (1) · [[:Category:5-HT3_antagonists|5-HT3 receptor antagonist]] (1) · [[:Category:Anesthetics|Anesthetic (historical)]] (1) · [[:Category:Anticoagulants|Anticoagulant]] (1) · [[:Category:Antiemetics|Antiemetic]] (1) · [[:Category:Antifungals|Antifungal (triazole)]] (1) · [[:Category:Antineoplastics|Antineoplastic (oral (1) · [[:Category:Arylcyclohexylamines|Arylcyclohexylamine]] (1) · [[:Category:Bacteriostatic_antibiotics|Bacteriostatic antibiotic]] (1) · [[:Category:Dissociatives|Dissociative]] (1) · [[:Category:Hormone_replacement_therapy|Hormone replacement therapy]] (1) · [[:Category:NMDA_receptor_antagonists|NMDA receptor antagonist]] (1) · [[:Category:Progestogens|Progestogen]] (1) · [[:Category:Retinoids|Retinoid]] (1) · [[:Category:Sex_hormones|Sex hormone]] (1) · [[:Category:Sigma-1_receptor_agonists|Sigma-1 receptor agonist]] (1) · [[:Category:Tetracycline_antibiotics|Tetracycline antibiotic]] (1) · [[:Category:Topical_retinoids|Topical retinoid]] (1) · [[:Category:Triazoles|Triazole]] (1) · [[:Category:Vitamin_K_antagonists|Vitamin K antagonist]] (1)
mechanism: (Click arrow to add another value)
uses:
None (11) · Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) · Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1) · Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) · '"`UNIQ--vote-00000063-QINU`"', '"`UNIQ--vote-00000064-QINU`"' (1) · '"`UNIQ--vote-00000374-QINU`"', '"`UNIQ--vote-00000375-QINU`"', '"`UNIQ--vote-00000376-QINU`"', '"`UNIQ--vote-00000377-QINU`"' (1) · '"`UNIQ--vote-00000475-QINU`"', '"`UNIQ--vote-00000476-QINU`"', '"`UNIQ--vote-00000477-QINU`"', '"`UNIQ--vote-00000478-QINU`"', '"`UNIQ--vote-00000479-QINU`"', '"`UNIQ--vote-0000047A-QINU`"', '"`UNIQ--vote-0000047B-QINU`"', '"`UNIQ--vote-0000047C-QINU`"' (1) · '"`UNIQ--vote-00000700-QINU`"', '"`UNIQ--vote-00000701-QINU`"', '"`UNIQ--vote-00000702-QINU`"', '"`UNIQ--vote-00000703-QINU`"', '"`UNIQ--vote-00000704-QINU`"' (1) · '"`UNIQ--vote-00000722-QINU`"', '"`UNIQ--vote-00000723-QINU`"', '"`UNIQ--vote-00000724-QINU`"', '"`UNIQ--vote-00000725-QINU`"' (1) · '"`UNIQ--vote-00000A42-QINU`"', '"`UNIQ--vote-00000A43-QINU`"', '"`UNIQ--vote-00000A44-QINU`"', '"`UNIQ--vote-00000A45-QINU`"', '"`UNIQ--vote-00000A46-QINU`"' (1) · '"`UNIQ--vote-00000BA0-QINU`"', '"`UNIQ--vote-00000BA1-QINU`"', '"`UNIQ--vote-00000BA2-QINU`"' (1)
starting dose:
None (11) · 10 mg/kg IV every 2 weeks (1) · 100 mg PO BID; rickettsial 200 mg/d; doxy-PEP 200 mg within 72 hours after condomless sex (1) · 4-8 mg PO or IV every 8 hours as needed; 16 mg single dose preoperatively for PONV prevention (1) · 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) · HRT cyclic: 200 mg PO HS days 1-12 of each month; continuous: 100 mg PO daily; ART luteal support 100 mg vaginal TID or 90 mg gel daily (1) · No current medical indication. Historical anesthetic dose 0.25 mg/kg IV (Sernyl). (1) · Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1) · Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses (1) · Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice (1) · Vulvovaginal: 150 mg PO single dose; oropharyngeal: 200 mg PO day 1, then 100 mg daily ×14 days; invasive candidiasis: 800 mg load, then 400 mg PO/IV daily; cryptococcal meningitis: 400-800 mg/d (1)
preparations:
None (11) · 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg tablets (color-coded by strength) (1) · 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1) · 200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1) · 350 mg/20 mL vial for IV infusion (1) · 4 mg, 8 mg, 24 mg tablets; 4 mg, 8 mg orally disintegrating tablets; 4 mg/5 mL oral solution; IV (2 mg/mL) (1) · 50 mg, 75 mg, 100 mg, 150 mg tablets and capsules; delayed-release; suspension; IV (1) · 50, 100, 150, 200 mg tablets; 10, 40 mg/mL oral suspension; 2 mg/mL IV (1) · Historical: Sernyl 25 mg tablets, 10 mg/mL injection (human); Sernylan 100 mg/mL injection (veterinary). Illicit: white crystalline powder, oily liquid, "dipped" cigarettes ("wet"), tablets. (1) · Oral 100, 200 mg capsules (peanut oil; check allergy); 100 mg vaginal insert (Endometrin); 4%, 8% vaginal gel (Crinone); IM 50 mg/mL (1) · Topical 0.01-0.1% creams, gels, micropsheres, lotions; oral 10 mg capsules (Vesanoid) (1)
fda max:
None (11) · 10 mg/kg q2w (1) · 1400 mg q4w (1) · 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) (1) · 800 mg/d (severe invasive disease) (1) · Indication-dependent; 200-400 mg/d oral typical (1) · N/A (no current medical indication) (1) · No fixed maximum; titrated to INR target (1) · Single doses ≤16 mg (FDA 2012 advisory withdrew the 32 mg single IV dose for QT-prolongation risk); 24-32 mg/d divided (1) · Topical: nightly; oral APL: 45 mg/m²/d (1) · ~200 mg/d for most indications; higher doses for severe infections (1)
routes:
None (11) · IM (2) · insufflated (1) · intramuscular (1) · IV (4) · IV (rarely used; same dose) (1) · IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1) · IV infusion every 4 weeks (1) · Oral (7) · oral (APL only) (1) · smoked (1) · Topical (1) · vaginal (1)
onset:
None (11) · 30 minutes PO; minutes IV (1) · Amyloid PET clearance within months; cognitive benefit over 18 months (1) · Anticoagulant effect at 24-72 hours; full INR effect 5-7 days (1) · Clinical improvement within 24-72 hours (1) · Hours (1) · Sedation/dizziness within hours of oral dose; endometrial effects over days (1) · Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1) · Smoked 2-5 min; insufflated 5-15 min; oral 30-60 min; IV / IM ~5-15 min (1) · Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days (1) · Weeks for psychosis/mood efficacy (1)
duration:
None (11) · 12 hours (1) · 2-5 days after stopping (factor II resynthesis-limited) (1) · 24 hours (1) · 4-12 hours (1) · 4-8 hours typical; longer at high doses; residual cognitive and perceptual effects up to 48 hours (1) · Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1) · N/A (1) · Ongoing dosing (1) · Oral: 8-12 hours; vaginal: 24+ hours; IM: days (1) · Treatment can be discontinued upon achieving amyloid clearance (1)
halflife:
None (11) · 16-22 hours'"`UNIQ--ref-0000047D-QINU`"' (1) · 3-6 hours (longer in hepatic impairment)'"`UNIQ--ref-00000378-QINU`"' (1) · 36-42 hours (R/S enantiomers differ; S-warfarin is 2-5× more potent and cleared by CYP2C9)'"`UNIQ--ref-00000705-QINU`"' (1) · Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) · Highly variable, 7-46 hours (mean ~21 h); lipophilic deposition in fat with delayed re-release contributes to wide range'"`UNIQ--ref-00000065-QINU`"' (1) · ~0.5-2 hours (oral)'"`UNIQ--ref-00000BA3-QINU`"' (1) · ~12.1 days (1) · ~30 hours (long, supports once-daily dosing and substantial drug-interaction window after discontinuation)'"`UNIQ--ref-00000A47-QINU`"' (1) · ~5-20 hours (oral micronized; highly variable)'"`UNIQ--ref-00000726-QINU`"' (1) · ~5-7 days (1)
bioavailability:
None (11) · 100% (IV) (2) · >90% (oral; not affected by food or gastric pH — a major practical advantage over itraconazole)'"`UNIQ--ref-00000A48-QINU`"' (1) · Adequate oral bioavailability (1) · Oral: very low (extensive first-pass); micronization improves uptake somewhat. Vaginal: high local effect with lower systemic levels (first-uterine-pass concentration)'"`UNIQ--ref-00000727-QINU`"' (1) · Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"' (1) · ~100% (oral)'"`UNIQ--ref-00000706-QINU`"' (1) · ~60% (oral)'"`UNIQ--ref-00000379-QINU`"' (1) · ~72% oral; ~85% smoked'"`UNIQ--ref-00000066-QINU`"' (1) · ~95% (oral; reduced by dairy, antacids, iron via divalent-cation chelation, though less than for tetracycline itself)'"`UNIQ--ref-0000047E-QINU`"' (1)
pregnancy: (Click arrow to add another value)
legal:
None (11) · Rx (1) · Rx; ARIA monitoring required (1) · Rx; REMS-like program for ARIA monitoring (1) · [[USLegal:DEA Schedule II|Schedule II]] controlled substance in US (rescheduled from Schedule III in 1978). No accepted medical use. UN Convention on Psychotropic Substances Schedule II internationally.'"`UNIQ--ref-00000067-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US (6)

Showing below up to 21 results in range #1 to #21.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"